Clinical Trials
12 trialsNCT00795665 2020-05-12
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Phase 2 Completed
NCT01186406 2019-02-15
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Duke University
Phase 2 Terminated
NCT00003176 2018-06-27
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00003484 2015-04-23
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Duke University
Phase 1 Completed
NCT00005081 2014-08-21
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
Duke University
Phase 2 Completed
NCT00003876 2013-06-26
Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00014573 2013-04-08
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00005637 2013-04-04
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003463 2013-02-18
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
Duke University
Phase 1 Completed
NCT00003567 2010-06-11
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00004028 2009-02-09
Carmustine in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004892 2009-02-09
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed